Objective: To study diagnostic principles and treatment methods of gout disease, hence to provide guidance for college teachers to prevent hyperuricemia. Methods: Literature review method was applied to study causes, diagnosis and treatments of gout attack. Investigation method was used to study the occurrence of hyperuricemia in a university in recent years, and its changing trend and causes were analyzed. Results: Medical therapy for Hyperuricemia mainly includes alleviating acute attack, inhibiting uric acid synthesis and promoting uric acid excretion. The incidence of hyperuricemia in male teachers in the university is about 20%, which is significantly higher than that of female teachers of the same age. Conclusions: Teachers in Colleges and universities are the high incidence group of gout, we should strengthen health education and guidance of gout prevention on them.

Li Miao, Yu Yang. Diagnosis and Treatment of Gout and Prevention of Hyperuricemia for Teachers in Colleges and Universities. Frontiers in Medical Science Research (2020) Vol. 2 Issue 2: 1-7. https://doi.org/10.25236/FMSR.2020.020201.

[1] Garrod AB(1863). The Nature and Treatment of Gout and Rheumatic Gout. 2nd ed. London: Walton and Maberly.
[2] Seegmiller JE, Howell RR, Malawista SE(1962). The inflammatory reaction to sodium urate: its possible relationship to the genesis of acute gouty arthritis. JAMA, vol. 180, no. 6, pp. 469-475.
[3] Roch-Ramel F, Diezi J.(1996). Renal transport of organic ions and uric acid. In: Diseases of the Kidney.Schrier RW, Gottschalk CE (Eds). 6th ed. Boston: Little Brown, pp. 231-249.
[4] Singh JA, Reddy SG, Kundukulam J.(2011) Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol, vol. 23, no. 2, pp.192-202.
[5] Dalbeth N, Stamp L(2014). Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis, vol. 73, no. 9, pp. 1598–1600.
[6] McQueen FM, Doyle A, Dalbeth N.(2014). Imaging in the crystal arthropathies. Rheum Dis Clin North Am, vol. 40, no. 2, pp.231-249.
[7] Janssens HJ, Fransen J, van de Lisdonk EH, et al. (2010).A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med, vol. 170, no. 13, pp.1120-1126.
[8] Richette P, Doherty M, Pascual E, et al.(2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, vol.76, no. 1, pp.29-42
[9] Khanna D, Fitzgerald JD, Khanna PP, et al.(2012). 2012 American College of Rheumatology guidelines for management of gout, part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken), vol. 64, no. 10, pp.1431-1446.
[10] Multi-disciplinary Expert Task Force on the diagnosis and treatment of hyperuricemia and its related diseases(2017). China multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases. Chinese Journal of Internal Medicine. vol. 56, no. 3, pp.235-248.
[11] Multi-disciplinary Expert Task Force on the diagnosis and treatment of hyperuricemia and its related diseases(2017). China multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases. Chinese Journal of Internal Medicine. vol.56, no. 3, pp.235-248.
[12] Janssen M, van de Lisdonk EH, et al.(2008). Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet, vol. 371, no. 6, pp. 1854 -1860.
[13] Richette P, Doherty M, Pascual E, et al.(2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, 2017, 76, no. 1, pp.29-42.
[14] Seth R, Kydd AS, Buchbinder R, et al.(2014). Allopurinol for chronic gout.Cochrane Database Syst Rev, no. 10, pp.CD006077.
[15] Becker MA, Schumacher HR Jr, Wortmann RL, et al.(2005). Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum, vol. 2, no. 3, pp.916-923.
[16] Khanna D, Fitzgerald JD, Khanna PP, et al.(2012). 2012 American College of Rheumatology guidelines for management of gout, part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken), vol. 64, no. 10, pp.1431-1446.
[17] Reinders MK, van Roon EN, Jansen TL, et al.(2009). Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis, vol. 68, no. 1, pp.51-56.
[18] Sundy JS, Baraf HS, Yood RA, et al.(2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA, vol. 306, no. 7, pp.711-720.